An Open-Label Study to Investigate the Effect of Renal Impairment on the Pharmacokinectics of Tenofovir Exalidex
Phase of Trial: Phase I
Latest Information Update: 08 Mar 2018
At a glance
- Drugs Tenofovir exalidex (Primary)
- Indications Hepatitis B
- Focus Pharmacokinetics
- Sponsors ContraVir Pharmaceuticals
- 06 Feb 2018 According to a ContraVir Pharmaceuticals media release, company plans to present additional results at future scientific meetings.
- 06 Feb 2018 Status changed from recruiting to completed, according to a ContraVir Pharmaceuticals media release.
- 19 Oct 2017 According to a ContraVir Pharmaceuticals media release, first patient has been dosed.